WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:		(11) International Publication Number:	WO 99/36001
A61F 2/06	A1	(43) International Publication Date:	22 July 1999 (22.07.99)

(21) International Application Number: PCT/US99/01012

(22) International Filing Date: 19 January 1999 (19.01.99)

(30) Priority Data: 09/009,400 20 January 1998 (20.01.98) US

(71) Applicant: HEARTSTENT CORPORATION [US/US]; 651 Campus Drive, St. Paul, MN 55112 (US).

(72) Inventor: TWEDEN, Katherine, S.; 1175 Ashley Lane, Mahtomedi, MN 55115 (US).


(74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, P.A., 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN-55402-4131 (US). (81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, IP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: FLEXIBLE TRANSMYOCARDIAL IMPLANT



(57) Abstract

A transmyocardial implant includes a hollow conduit adapted to be inserted into and retained within the heart wall of a heart chamber containing oxygenated blood. The conduit is in blood-flow communication with blood contained within the chamber. A natural blood vessel graft having a first end is secured to the conduit for blood flow from the chamber to flow into the graft. The graft has a second end secured to the coronary vessel with an opening of the second end in blood flow communication with a lumen of the coronary vessel. The conduit and graft defining a blood flow path between the openings of the first and second ends.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

		i.				
Albania	ES	Spain	LS	Lesotho	SI	Slovenia
Armenia	FI	Finland	LT	Lithuania		Slovakia
Austria	FR	France	LU		SN	Senegal
Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
Azerbaijan	GB	United Kingdom	MC	Monaco	-	Chad
Bosnia and Herzegovina	GE	Georgia	MD			Togo
Barbados	GH	Ghana	MG .	-	_	Tajikistan
Belgium	GN	Guinea	MK	•	TM	Turkmenistan
Burkina Faso	GR	Greece			TR	Turkey
Bulgaria	HU	Hungary	ML	Mali		Trinidad and Tobago
Benin	IE	Ireland	MN	Mongolia		Ukraine
Brazil	IL	Israel	MR			Uganda
Belarus	IS	Iceland	MW	,	-	United States of America
Canada	IT	Italy	MX			Uzbekistan
Central African Republic	JР	Japan	NE			Viet Nam
Congo	KE	•		-		Yugoslavia
Switzerland	KG	· · · · · · · · · · · · · · · · · · ·				Zimbabwe
Côte d'Ivoire	KР			•	2	zoabwe
Cameroon						
China	KR					
Cuba	. KZ	Kazakstan		-		
Czech Republic						
Germany	-					
Denmark						
Estonia	LR	Liberia	SG			
	Armenia Austria Australia Azerbaijan Bosnia and Herzegovina Barbados Belgium Burkina Faso Bulgaria Benin Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon China Cuba Czech Republic Germany Denmark	Armenia FI Austria FR Australia GA Azerbaijan GB Bosnia and Herzegovina GE Barbados GH Belgium GN Burkina Faso GR Bulgaria HU Benin IE Brazil IL Belarus IS Canada IT Central African Republic JP Congo KE Switzerland KG Côte d'Ivoire KP Cameroon China KR Cuba KZ Czech Republic LC Germany LI Denmark	Armenia FI Finland Austria FR France Australia GA Gabon Azerbaijan GB United Kingdom Bosnia and Herzegovina GE Georgia Barbados GH Ghana Belgium GN Guinea Burkina Faso GR Greece Bulgaria HU Hungary Benin IE Ireland Brazil IL Israel Belarus IS Iceland Canada IT Italy Central African Republic JP Japan Congo KE Kenya Switzerland KG Kyrgyzstan Côte d'Ivoire KP Democratic People's Cameroon Republic Of Korea China KR Republic of Korea Cuba KZ Kazakstan Czech Republic LE Saint Lucia Germany LI Liechtenstein Denmark LK Sri Lanka	Armenia FI Finland LT Austria FR France LU Australia GA Gabon LV Azerbaijan GB United Kingdom MC Bosnia and Herzegovina GE Georgia MD Barbados GH Ghana MG Belgium GN Guinea MK Burkina Faso GR Greece Bulgaria HU Hungary ML Benin IE Ireland MN Brazil IL Israel MR Belarus IS Iceland MW Canada IT Italy MX Central African Republic JP Japan NE Congo KE Kenya NL Switzerland KG Kyrgyzstan NO Côte d'Ivoire KP Democratic People's NZ Cameroon REPUBLIC Saint Lucia RU Cermany LI Liechtenstein SD Denmark LK Sri Lanka SE	Armenia FI Finland LT Lithuania Austria FR France LU Luxembourg Australia GA Gabon LV Latvia Azerbaijan GB United Kingdom MC Monaco Bosnia and Herzegovina GE Georgia MD Republic of Moldova Barbados GH Ghana MG Madagascar Belgium GN Guinea MK The former Yugoslav Burkina Faso GR Greece Republic of Macedonia Bulgaria HU Hungary ML Mali Benin IE Ireland MN Mongolia Brazil IL Israel MR Mauritania Belarus IS Iceland MW Malawi Canada IT Italy MX Mexico Central African Republic JP Japan NE Niger Congo KE Kenya NL Netherlands Switzerland KG Kyrgyzstan NO Norway Côte d'Ivoire KP Democratic People's NZ New Zealand Cameroon Republic of Korea PL Poland China KR Republic of Korea PT Portugal Cuba KZ Kazakstan RO Romania Czech Republic Germany LI Liechtenstein SD Sudan Denmark LK Sri Lanka SE Sweden	Armenia FI Finland LT Lithuania SK Austria FR France LU Luxembourg SN Australia GA Gabon LV Latvia SZ Azerbaijan GB United Kingdom MC Monaco TD Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Barbados GH Ghana MG Madagascar TJ Belgium GN Guinea MK The former Yugoslav TM Burkina Faso GR Greece Republic of Macedonia TR Bulgaria HU Hungary ML Mali TT Benin IE Ireland MN Mongolia UA Brazil IL Israel MR Mauritania UG Belarus IS Iceland MW Malawi US Canada IT Italy MX Mexico UZ Central African Republic JP Japan NE Niger VN Congo KE Kenya NL Netherlands YU Switzerland KG Kyrgyzstan NO Norway ZW Côte d'Ivoire KP Democratic People's NZ New Zealand Cameroon Republic of Korea PL Poland China KR Republic of Korea PT Portugal Cuba KZ Kazakstan RO Romania Czech Republic LC Saint Lucia RU RU Russian Pederation Germany LI Liechtenstein SD Sudan Denmark LK Sri Lanka SE Sweden

WO 99/36001

5

10

15

20

25

30

FLEXIBLE TRANSMYOCARDIAL IMPLANT

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention pertains to an implant for passing blood flow directly between a chamber of the heart and a coronary vessel. More particularly, this invention pertains to a flexible transmyocardial implant.

2. Description of the Prior Art

Commonly assigned and co-pending U.S. Patent Application Serial No. 08/882,397 filed June 25, 1997, entitled "Method and Apparatus for Performing Coronary Bypass Surgery", and filed in the name of inventors Mark B. Knudson and William L. Giese, teaches an implant for defining a blood flow conduit directly from a chamber of the heart to a lumen of a coronary vessel. An embodiment disclosed in the aforementioned application teaches an L-shaped implant in the form of a rigid conduit having one leg sized to be received within a lumen of a coronary artery and a second leg sized to pass through the myocardium and extend into the left ventricle of the heart. As disclosed in the above-referenced application, the conduit is rigid and remains open for blood flow to pass through the conduit during both systole and diastole. The conduit penetrates into the left ventricle in order to prevent tissue growth and occlusions over an opening of the conduit.

Commonly assigned and co-pending U.S. patent application Serial No. 08/944,313 filed October 6, 1997, entitled "Transmyocardial Implant", and filed in the name of inventors Katherine S. Tweden, Guy P. Vanney and Thomas L. Odland, teaches an implant such as that shown in the aforementioned '397 application with an enhanced fixation structure. The enhanced fixation structure includes a fabric surrounding at least a portion of the conduit to facilitate tissue growth on the exterior of the implant.

Implants such as those shown in the aforementioned applications include a portion to be placed within a coronary vessel and a portion to be placed within the myocardium. The implants disclosed in the above-mentioned applications are rigid structures. Being rigid, the implants are restricted in use. For example, an occluded

WO 99/36001 PCT/US99/01012

site may not be positioned on the heart in close proximity to a heart chamber containing oxygenated blood. To access such a site with a rigid, titanium implant, a very long implant must be used. A long implant results in a long pathway in which blood will be in contact with the material of the implant. With non-biological materials, such as titanium, a long residence time of blood against such materials increases the probability of thrombus. The risk can be reduced with anti-thrombotic coatings. Moreover, a rigid implant can be difficult to place while achieving desired alignment of the implant with the vessel. A flexible implant will enhance placement of the implant. Unfortunately, flexible materials tend to be non-biostable and trombogenic and may collapse due to contraction of the heart during systole.

SUMMARY OF THE INVENTION

According to a preferred embodiment of the present invention, a transmyocardial implant is disclosed for establishing a blood flow path through a myocardium between a heart chamber and a lumen of a coronary vessel residing on an exterior of the heart. The implant includes a hollow conduit adapted to be inserted into and retained within the heart wall of a heart chamber containing oxygenated blood. The conduit is in blood-flow communication with blood contained within the chamber. A natural blood vessel graft is secured to the conduit for blood from the chamber to flow into the graft. The graft is secured to the coronary vessel in blood flow communication with a lumen of the coronary vessel. The conduit and graft define a blood flow path between the heart chamber and the vessel.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a side sectional view of an implant according to the present invention; and

FIG. 2 is a side sectional view of an implant according to the present invention shown in place in a human heart wall with the implant establishing a direct blood flow path from a heart chamber to a coronary vessel.

5

10

15

20

25

5

10

15

20

25

30

DESCRIPTION OF THE PREFERRED EMBODIMENT

With initial reference to FIG. 1, an implant 10 is shown including a hollow, rigid cylindrical conduit 12 and a natural tubular graft vessel 14. The conduit 12 may be formed of titanium or other rigid biocompatible material such as pyrolytic carbon or may be titanium coated with pyrolytic carbon. The material of the conduit 12 is preferably a rigid material in order to withstand contraction forces of the myocardium. While the conduit 12 is described as a solid, rigid cylinder, the conduit 12 can be any structure (e.g., an expanded stent) suitable to hold open a path through the myocardium during both systole and diastole.

The conduit 12 is sized to extend through the myocardium 80 of the human heart to project into the interior of a heart chamber 82 (preferably, the left ventricle) by a distance of about 5 mm. By way of non-limiting example, the conduit 12 will have an axial length L of about 25 - 35 mm and an outside diameter D₀ of about 3 millimeters and an internal diameter D₁ of about 2 millimeters to provide a wall thickness of about .5 millimeters. The conduit 12 extends from a first end 16 to a second end 18. While not shown, the second end 18 of the conduit 12 may be provided with a flange to stop insertion of the conduit 12 into the myocardium 80. Such a flange will insure penetration of the second end 16 into the left ventricle 82 and will provide a convenient location for a surgeon to suture the conduit 12 to the myocardium. Adjacent to the lower end 16, the exterior wall of the conduit 12 is provided with a circumferential groove 22, the purpose of which will be described.

As discussed more fully in the afore-mentioned commonly assigned and copending U.S. Patent Application Serial No. 08/944,313, the conduit 12 may be provided with tissue-growth inducing material 20 to further immobilize the conduit 12 within the myocardium 80. The material 20 is positioned adjacent upper end 18 and spaced from lower end 16 and groove 22. The material 20 surrounds the exterior of the conduit 12 and may be a polyester woven sleeve or sintered metal to define pores into which tissue growth from the myocardium 80 may occur.

The natural vessel 14 graft has first and second ends 30, 32. The first end 30 of the graft 14 is inserted through the interior of the conduit 12. The first end 30 is wrapped around the first end 16 of the conduit 12 such that the first end 30 of the

WO 99/36001 PCT/US99/01012

graft 14 partially covers the exterior of the conduit 12 adjacent the first end 16 of the conduit 12 and covers the groove 22. The first end 30 of the graft 14 is secured to the conduit 12 by sutures 34 tightly placed around the exterior of the graft 14 overlying the groove 22.

5

10

15

20

The conduit 12 and attached graft 14 are placed in the myocardium 80 with the first end 16 protruding into the left ventricle 82. The implant 10 thus defines an open blood flow path 60 having a first end 62 in blood flow communication with the left ventricle 82. A second end 64 of the blood flow path 60 communicates directly with the lumen 84 of the coronary vessel 86 lying on an exterior of the heart wall 80. To bypass an obstruction in a coronary artery, the end 32 of the graft 14, is anastomosed to the artery 32 with sutures (not shown) as is done in conventional coronary artery bypass procedures. The end 32 is secured to the artery 86 distal to the obstruction.

With the above-described embodiment, the implant 10 permits revascularization from the left ventricle 82 to a coronary vessel such as a coronary artery (or a coronary vein in the event of a retrograde profusion procedure). The use of an elongated, flexible graft 14 permits revascularization where the vessel 86 is not necessarily in overlying relation to the chamber 82. For example, the implant 10 permits direct blood flow between the left ventricle 82 and a vessel 86 overlying the right ventricle (not shown). The use of a natural graft 14 results in blood flowing through path 60 being exposed only to natural biological material thereby reducing risk of thrombosis. As shown in FIG. 2, the graft 14 is wrapped around the conduit 12 so that no portion of the conduit 12 is in contact with blood within the left ventricle 82.

25

Any suitable graft may be used. For example, the graft 14 may be an artery or vein harvested from the patient. Such harvesting is common in traditional bypass surgeries. The present invention permits harvesting a much shorter length of vessel than would be otherwise required in conventional bypass surgeries. In addition to grafts harvested from the patient, other grafts could be used. These include cryopreserved grafts or bovine or umbilical vein glutaraldehyde treated vessels.

30

Certain veins, for example the saphenous vein, include natural valves 70. In the event such veins are selected as graft 14, the graft 14 is aligned so that the valves 5

70 are positioned to provide unobstructed flow from the left ventricle 82 to the vessel 86 as illustrated by arrow A in FIG. 2. The valves 70 act to obstruct reverse flow to the left ventricle.

Having disclosed the present invention in a preferred embodiment, it will be appreciated that modifications and equivalents may occur to one of ordinary skill in the art having the benefits of the teachings of the present invention. It is intended that such modifications shall be included within the scope of the claims which are appended hereto.

What is claimed is:

1. An apparatus for use in a coronary artery bypass procedure at a coronary vessel disposed lying on an exterior of a heart wall, the apparatus comprising;

a hollow conduit adapted to be inserted into and retained within the heart wall of a heart chamber containing oxygenated blood with the conduit in blood-flow communication with blood contained within the chamber;

a natural blood vessel graft having a first end secured to said conduit for blood flow from said chamber to flow into said graft;

said graft having a second end secured to the coronary vessel with an opening of the second end in blood flow communication with a lumen of the coronary vessel; and

the conduit and graft defining a blood flow path between the openings of the first and second ends.

- 2. An apparatus according to claim 1 wherein the conduit is sized to maintain a flow path through the conduit in response to cardiac contraction during systole.
- 3. An apparatus according to claim 1 wherein the first end of the graft is wrapped around a first end of the conduit.
- 4. An apparatus according to claim 1 wherein the graft has internal valves limiting flow to a direction from the first end to the second end.
- 5. An apparatus according to claim 3 wherein the graft is a saphenous vein.
- 6. A method for performing a coronary bypass procedure at a coronary vessel disposed lying on an exterior of a heart wall, the method comprising:

securing a first end of a natural vessel graft to a hollow conduit;

inserting the hollow conduit through the heart wall where the conduit and graft define a blood flow path between the first end and a second end of the graft and with the first end in blood flow communication with the heart chamber;


securing the second end to the vessel to direct blood to flow from the blood flow path into the vessel.


- 7. A method according to claim 6 wherein the coronary vessel is a coronary artery.
- 8. A method according to claim 6 wherein the conduit is selected to maintain an open blood flow path through the conduit during systole.
- 9. A method according to claim 6 wherein the first end of the graft is wrapped around an end of the conduit.
- 10. A method according to claim 6 wherein the graft is selected to have internal valves limiting flow to a direction from the first end to the second end.
- 11. A method according to claim 10 wherein the graft is a saphenous vein.

82

8

02





INTERNATIONAL SEARCH REPORT

Int tional Application No PCT/US 99/01012

IPC 6	FICATION OF SUBJECT MATTER A61F2/06							
*	International Patent Classification (IPC) or to both national classification	tion and IPC						
	SEARCHED							
Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61F								
			1					
Documentat	ion searched other than minimum documentation to the extent that su	sch documents are included in the fields se	arched					
Electronic d	ata base consulted during the international search (name of data bas	e and, where practical, search terms used)					
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT							
Category *	Citation of document, with indication, where appropriate, of the rele	want passages	Relevant to claim No.					
			THOUSE IN TO GRAIN TO.					
Υ	MUNRO ET AL: "The possibility of		1,2					
	myocardial revascularisation by c	reation	-,-					
	of a left ventriculocoronary arte fistula"	ry						
	JOURNAL OF THORACIC AND CARDIOVA	SCULAR						
	SURGERY,	·						
	vol. 58, no. 1, 1 July 1969, page	s 25-32,						
	XP002103020 see figure 1							
Y	US 4 769 031 A (MCGOUGH ET AL)		1,2					
	6 September 1988 see column 3, line 42 - column 4,	line 2						
1	figures 1,2,4	11116 Z,						
ļ								
			•					
Furt	her documents are listed in the continuation of box C.	X Patent family members are listed	in annex.					
° Special ca	ategories of cited documents:	"T" later document published after the inte	mational filing date					
"A" docum	"A" document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the							
"E" earlier	document but published on or after the international	invention "X" document of particular relevance; the o	claimed invention					
"L" docume	ent which may throw doubts on priority claim(s) or	cannot be considered novel or cannot involve an inventive step when the do	be considered to					
citatio	is cited to establish the publication date of another in or other special reason (as specified)	"Y" document of particular relevance; the cannot be considered to involve an in						
"O" docum	ent referring to an oral disclosure, use, exhibition or means	document is combined with one or ma ments, such combination being obvio	ore other such docu-					
"P" docum	ent published prior to the international filing date but han the priority date claimed	in the art. "&" document member of the same patent						
Date of the	actual completion of the international search	Date of mailing of the international search report						
1	.8 May 1999	28/05/1999						
Name and	mailing address of the ISA	Authorized officer	· · · · · · · · · · · · · · · · · · ·					
	European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk							
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Smith, C						

INTERNATIONAL SEARCH REPORT

...ternational application No.

PCT/US 99/01012

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 6-11 because they relate to subject matter not required to be searched by this Authority, namely: Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is tacking (Continuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

tional Application No

Information on patent family members PCT/US 99/01012 Publication date Patent document cited in search report Publication date Patent family member(s) US 4769031 Α 06-09-1988 NONE